A Postdoctoral position is available in 2025 for a highly-motivated, enthusiastic individual in the NIH-funded group of Dr. Weiran Feng in the Cancer Epigenetics Institute, Fox Chase Cancer Center. Opening in Jan 2025, the Feng group will be studying the mechanisms of prostate cancer development and therapy resistance. We leverage state-of-the-art animal and organoid models, genetic engineering, functional genetics and genomic approaches to investigate the molecular mechanisms driving prostate cancer initiation, progression, and therapy resistance. Our research explores both cancer cell-intrinsic pathways and the cell-cell interactions within the tumor microenvironment. Our overarching goal is to make mechanistic discoveries that drive novel therapy development to improve clinical benefits.

Interested applicants should be highly dedicated, enthusiastic and have experience publishing peer reviewed...